Skip to main content
SpringerLink
Log in

Laboratory studies to develop general principles for the adjuvant treatment of breast cancer with antiestrogens: Problems and potential for future clinical applications

  • Published:
Breast Cancer Research and Treatment Aims and scope Submit manuscript

Summary

The general pharmacology of tamoxifen in animals and man is reviewed with particular reference to the longterm adjuvant therapy of node-positive breast cancer. Rats with dimethylbenzanthracene (DMBA)-induced mammary carcinomata have been used extensively as a laboratory model to study hormone-dependent cancer. The administration of a 30-day course of tamoxifen (50 µg daily) starting 5, 15, 30, or 50 days after DMBA caused a delay in tumor appearance and decrease in the cumulative number of tumors that were induced by 200 days. Similarly, the administration of increasing doses of tamoxifen (0.2, 3, 50, and 800 µg daily) between 30 and 60 days after DMBA produced a dose-related delay in tumor appearance and a decrease in the cumulative number of tumors at 200 days. Since the tumors that were induced after tamoxifen still responded to ovariectomy, tamoxifen appears to act as an inhibitor of the tumor cell cycle rather than as a tumoricidal agent in this model. This principle was exemplified by comparing a short course (30 day) with a continuous course (170 day) of tamoxifen initiated 30 days after DMBA. The short course of therapy only delayed tumor appearance whereas continuous therapy maintained 90% of the animals in a tumor-free state. These data strongly support the use of long-term (up to five-year) adjuvant therapy with tamoxifen in patients as a suppressive therapy for homone-sensitive metastases.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Fisher B, Carbone PP, Econamou SG, Frelick R, Glass A, Lerner H, Redmond C, Zelen M, Band P, Katrych DL, Wolmark N, Fisher ER: L-Phenylalanine mustard (L-PAM) in the management of primary breast cancer: a report of early findings. N Engl J Med 292:117–122, 1975

    Google Scholar 

  2. Bonadonna G, Brusamolino E, Valagussa P, Rossi A, Brugnatelli L, Branbilla C, DeLena M, Tancini G, Bejetta, Musumeci R, Veronesi U: Combination chemotherapy as an adjuvant treatment in operable breast cancer. N Engl J Med 297:405–410, 1976

    Google Scholar 

  3. Mouridsen H, Palshof T, Patterson J, Battersby L: Tamoxifen in advanced breast cancer. Cancer Treat Rev 5:131–141, 1978

    PubMed  Google Scholar 

  4. Hubay CA, Pearson OH, Marshall JS, Rhodes RS, DeBame SM, Rosenblatt J, Mansour EG, Hermann RE, Jones JC, Flynn WJ, Eckert C, McGuire WL, and 27 participating invesigators: Adjuvant chemotherapy, antiestrogen therapy and immunotherapy for stage II breast cancer. Cancer 46:2805–2808, 1980

    PubMed  Google Scholar 

  5. Fisher B, Redmond C, Brown A, Wolmark N, Wittliff J, Fisher E. Plotkin D, Bowman D, Sachs S, Wolter J, Frelick R, Desser R, LiCalzi N, Geggie P, Campbell T, Elias EG, Prager D, Koontz P, Volk TT, Dimitrov N, Gardner B, Lerner H, Shibata H, and other NSABP investigators: Treatment of primary breast cancer with chemotherapy and tamoxifen. N Engl J Med 305:1–6, 1981.

    PubMed  Google Scholar 

  6. Katzenellenbogen BS, Bhakoo HS, Ferguson ER, Lan NC, Tatee T, Tsai TLS,, Katzenellenbogen JA: Estrogen and antiestrogen action in reproductive tissues and tumors. Rec Prog Horm Res 35:259–300, 1979

    PubMed  Google Scholar 

  7. Sutherland RL, Jordan VC (eds): Nonsteroidal Antioestrogens: Molecular Pharmacology and Antitumour Activity. Academic Press, Sydney, 1981

    Google Scholar 

  8. Sutherland RL, Murphy LC: Mechanisms of oestrogen antagonism by nonsteroidal antioestrogens. Mol Cell Endocrinol 25:5–23, 1982

    PubMed  Google Scholar 

  9. Jordan VC: Pharmacology of antiestrogens.In DP Rose (ed) Endocrinology of Cancer III. CRC, Boca Raton, FL, 1982, pp 129–173

    Google Scholar 

  10. Heel RC, Brogden RN, Speight TM, Avery GS: Tamoxifen: a review of its pharmacological properties and therapeutic use in the treatment of breast cancer. Drugs 16:1–24, 1978

    PubMed  Google Scholar 

  11. Furr BJA, Jordan VC: The Pharmacology and clinical uses of tamoxifen. Pharmacol Ther (in press 1983)

  12. Harper MJK, Walpole AL. Contrasting endocrine activities ofcis andtrans isomers in a series of substituted triphenylethylenes. Nature (London) 212:87, 1967

    Google Scholar 

  13. Jordan VC, Haldemann B, Allen KE: Geometric isomers of substituted triphenylethylenes and antiestrogen action. Endocrinology 108:1353–1361, 1981

    PubMed  Google Scholar 

  14. Fromson JM, Pearson S, Bramah S: The metabolism of tamoxifen (ICI 46,474). In laboratory animals. Xenobiotica 3:693–709, 1973

    PubMed  Google Scholar 

  15. Jordan VC, Collins MM, Rowsby L, Prestwich G: A monohydroxylated metabolite of tamoxifen with potent antioestrogenic activity. J Endocrinol 75:305–316, 1977

    PubMed  Google Scholar 

  16. Borgna JL, Rochefort H: Hydroxylated metabolites of tamoxifen are formed in vivo and bound to estrogen receptors in target tissues. J Biol Chem 256:859–868, 1981

    PubMed  Google Scholar 

  17. Allen KE, Clark ER, Jordan VC: Evidence for the metabolic activation of nonsteroidal antioestrogens: a study of structure-activity relationships. Br J Pharmacol 71:83–91, 1980

    PubMed  Google Scholar 

  18. Lieberman ME, Jordan VC, Fritsch M, Santos MA, Gorski J: Direct and reversible inhibition of estradiolstimulated prolactin synthesis by antiestrogens in vitro. J Biol Chem 258:4734–4740, 1983

    PubMed  Google Scholar 

  19. Winneker RC, Clark JH: Antiestrogen binding sites in the rat uterus, liver and blood. Breast Cancer Res Treat 2:279, 1982

    Google Scholar 

  20. Jordan VC, Prestwich G: Binding of [3H] tamoxifen in rat uterine cytosols: a comparison of swinging bucket and vertical tube rotor sucrose density gradient analysis. Mol Cell Endocrinol 8:179–188 1977

    PubMed  Google Scholar 

  21. Jordan VC, Bowser-Finn RA: Binding of [3H] monohydroxytmoxifen by immature rat tissues in vivo. Endocrinology 110:1281–1291, 1982

    PubMed  Google Scholar 

  22. Nicholson RI, Syne JS, Daniel CP, Griffith K: The binding of tamoxifen to estrogen receptor proteins under equilibrium and non-equilibrium conditions. Eur J Cancer 15:317–329, 1979

    PubMed  Google Scholar 

  23. Tate AC, DeSombre ER, Greene GL, Jordan VC, Jensen EV: Interaction of estrophilin-specific monoclonal antibodies with [3H] estradiol— and [3H] monohydroxytamoxifen—estrogen receptor complex from breast tumors. Breast Cancer Res Treat 2:277, 1982

    Google Scholar 

  24. Jordan VC, Dix CJ, Rowsby L, Prestwich G: Studies on the mechanism of action of the non-steroidal antioestrogen tamoxifen (ICI 46,474) in the rat. Mol Cell Endocrinol 7:177–192, 1977

    PubMed  Google Scholar 

  25. Dix CJ, Jordan VC: Subcellular effects of monohydroxytamoxifen in the rat uterus: steroid receptors and mitosis. J Endocrinol 85:393–404, 1980

    PubMed  Google Scholar 

  26. Horwitz KB, McGuire WL: Nuclear mechanisms of estrogen action. J Biol Chem 253:8185–8191, 1978

    PubMed  Google Scholar 

  27. Murphy LC, Sutherland RL: A high-affinity binding site for the antioestrogens, tamoxifen and CI628, in immature rat uterine cytosol which is distinct from the oestrogen receptor. J Endocrinol 91:155–161, 1981

    PubMed  Google Scholar 

  28. Sudo K, Monsma FJ, Katzenellenbogen BS: Antiestrogen binding sites distinct from the estrogen receptor: subcellular localisation, ligand specificity and distribution in tissues of the rat. Endocrinology 112:425–434, 1983

    PubMed  Google Scholar 

  29. Jensen EV, DeSombre ER: Estrogen receptor interactions. Science 182:126–134, 1973

    PubMed  Google Scholar 

  30. Stephenson RP: A modification of receptor theory. Br J Pharmacol 2:379–392, 1956

    Google Scholar 

  31. Ariens EJ, Simonis AM: A molecular basis for drug action. J Pharm Pharmacol 16:136–157, 1964

    PubMed  Google Scholar 

  32. Huggins C, Grand LC, Brillantes P: Mammary cancer induced by a single feeding of polynuclear hydrocarbons and its suppression. Nature (London) 189:204–207, 1961

    Google Scholar 

  33. Sterental A, Dominguez JM, Weissman C, Pearson OH: Pituitary role in the estrogen dependency of experimental mammary cancer. Cancer Res 23:481–484, 1963

    PubMed  Google Scholar 

  34. Jordan VC: Laboratory models of hormone-dependent cancer.In BJA Furr (ed). Clinics in Oncology, Vol. 1. WB Saunders, Philadelphia, 1982, pp 21–40

    Google Scholar 

  35. Manni A, Trujillo JE, Pearson OH: Predominant role of prolactin in stimulating the growth of 7,12-dimethylbenz (a) anthracene-induced rat mammary tumor. Cancer Res 37:1216–1220, 1977

    PubMed  Google Scholar 

  36. Nicholson RI, Golder MP: The effect of synthetic antioestrogens on the growth and biochemistry of rat mammary tumors. Eur J Cancer 11:571–579, 1975

    PubMed  Google Scholar 

  37. Jordan VC, Dowse LJ: Tamoxifen as an antitumour agent: effect on oestrogen binding. J Endocrinol 68:297–303, 1976

    PubMed  Google Scholar 

  38. Jordan VC, Jaspan T: Tamoxifen as an antitumour agent: oestrogen binding as a predictive test for tumor response. J Endocrinol 68:453–460, 1976

    PubMed  Google Scholar 

  39. Nicholson RI, Golder MP, Davis P, Griffith K: Effects of oestradiol-17β and tamoxifen on total and accessible cytoplasmic oestradiol-17β receptors in DMBA-induced rat mammary tumours. Eur J Cancer 12:711–719, 1976

    PubMed  Google Scholar 

  40. Jordan VC, Koerner S, Robinson C: Inhibition of estrogen stimulated prolactin release by antioestrogens. J Endocrinol 65:151–152, 1975

    PubMed  Google Scholar 

  41. Jordan VC, Koerner S: Tamoxifen as an antitumour agent: role of estradiol and prolactin. J Endocrinol 68:305–311, 1976

    PubMed  Google Scholar 

  42. Labhsetwar AP: Role of estrogen in ovulation: a study using the estrogen antagonist ICI 46,474. Endocrinology 87:542–551, 1970

    PubMed  Google Scholar 

  43. Watson J, Howson JWH: Inhibition by tamoxifen of the stimulatory action of FSH on oestradiol-17b biosynthesis by rat ovaries in vitro. J Reprod Fertil 49:375–380, 1977

    PubMed  Google Scholar 

  44. Jordan VC: Antitumour activity of the antioestrogen ICI 46,474 (tamoxifen) in the dimethylbenzanthracene (DMBA)-induced rat mammary carcinoma model. J Steroid Biochem 5:354, 1974

    Google Scholar 

  45. Jordan VC: Effect of tamoxifen (ICI 46,474) on initiation and growth of DMBA-induced rat mammary carcinomata. Eur J Cancer 12:419–424, 1976

    PubMed  Google Scholar 

  46. Jordan VC, Allen KE: Evaluation of the antitumour activity of the nonsteroidal antioestrogen monohydroxytamoxifen in the DMBA-induced rat mammary carcinoma model. Eur J Cancer 16:239–251, 1980

    PubMed  Google Scholar 

  47. Jordan VC, Dix CJ, Allen KE: The effectiveness of long term tamoxifen treatment in a laboratory model for adjuvant hormone therapy of breast cancer.In Adjuvant Therapy of Cancer II. SE Salmon and SE Jones (eds). Grune and Stratton, New York, 1979, pp 19–26

    Google Scholar 

  48. Wilson AJ, Tehrani F, Baum M: Adjuvant tamoxifen therapy for early breast cancer: an experimental study with reference to oestrogen and progesterone receptors. Br J Surg 69:121–125, 1982

    PubMed  Google Scholar 

  49. Rose DP, Pruitt B, Stauber P, Erturk E, Bryan GT: Influence of dosage schedule on the biological characteristics of N-nitrosomethyl urea-induced rat mammary tumors. Cancer Res 40:235–239, 1980

    PubMed  Google Scholar 

  50. Turcot-LeMay L, Kelly PA: Characterization of estradiol, progesterone and prolactin receptors in nitrosomethyl urea-induced mammary tumors and effect of antiestrogen treatment on the development and growth of these tumors. Cancer Res 40:3232–3240, 1980

    PubMed  Google Scholar 

  51. Lippman ME, Aitken SC, Allegra JC: Regulation of growth and DNA synthesis by oestrogens and antioestrogens in human breast cancer cell lines.In RL Sutherland, VC Jordan (eds). Non-steroidal Antioestrogen. Academic Press, Sydney, 1981, pp 365–395

    Google Scholar 

  52. Tormey DC, Jordan VC: Adjuvant use of tamoxifen for at least five years in node positive breast cancer.In Proceedings of the International Association for Breast Cancer Research, March 20–24, Denver, 1982

  53. Nevasaari K, Heikkinein J, Taskinen PJ: Tamoxifen and thrombosis. Lancet 2:946–947, 1978

    Google Scholar 

  54. Hendrick A, Subramanian VP: Tamoxifen and thromboembolism. JAMA 243:514–515, 1980

    PubMed  Google Scholar 

  55. Sakai F, Cheix F, Clavel M, Colon J, Mayer M, Pommatau E, Saez S: Increases in steroid binding globulins induced by tamoxifen in patients with carcinoma of the breast. J Endocrinol 76:219–226,8

  56. Enk RE, Cunningham VM, Bringhamton CN: Tamoxifen treatment of metastatic breast cancer and antithrombin III levels [abstr C85].In Proceedings of the 17th Annual Meeting of ASCO, April 30–May 2, 1981

  57. Fex G, Adelsson G, Mattson W: Oestrogen-like effects of tamoxifen on the concentration of proteins in plasma. Acta Endocrinol (Kbh) 97:109–113, 1981

    Google Scholar 

  58. Jordan VC: Metabolites of tamoxifen in animals and man: identification, pharmacology and significance. Breast Cancer Res Treat 2:123–138, 1982

    PubMed  Google Scholar 

  59. Adam HK, Gay MA, Moore RH: Measurement of tamoxifen in serum by thin layer densitometry. J Endocrinol 84:35–42, 1980

    PubMed  Google Scholar 

  60. Mendenhall DW, Kobyashi H, Shih FML, Sternson LA, Higuchi T, Fabian C: Clinical analysis of tamoxifen, an antineoplastic agent, in plasma. Clin Chem 24:1518–1524, 1978

    PubMed  Google Scholar 

  61. Brown RR, Bain RR, Jordan VC: Determination of tamoxifen and metabolites in human serum by highperformance liquid chromatography with post-column-fluorescence activation. J Chromatogr 272:351–358, 1983

    PubMed  Google Scholar 

  62. Daniel CP, Gask II SJ, Bishop H, Nicholson RI: Determination of tamoxifen and an hydroxylated metabolite in plasma from patients with advanced breast cancer using gas chromatography-mass spectometry. J Endocrinol 83:401–408, 1979

    PubMed  Google Scholar 

  63. Fromson JM, Pearson S, Bramah S: The metabolism of tamoxifen (ICI 46,474). I. In laboratory animals. Xenobiotica 3:693–709, 1973

    PubMed  Google Scholar 

  64. Jordan VC, Bain RR, Brown RR, Gosden B, Santos MA: Determination and pharmacology of a new hydroxylated metabolite of tamoxifen observed in patient sera during therapy for advanced cancer. Cancer Res 43:1446–1450, 1983.

    PubMed  Google Scholar 

  65. Foster AB, Griggs LJ, Jarman M, Van Maanen JMS, Schulter HR: Metabolism of tamoxifen by rat liver microsomes: formation of the N-oxide, a new metabolite. Biochem Pharmacol 29:1977–1979, 1980

    PubMed  Google Scholar 

  66. Bates DJ, Foster AB, Griggs LJ, Jarman M, Leclerq G, Devleeschouwer N: Metabolism of tamoxifen by isolated rat hepatocytes: antiestrogenic activity of tamoxifen Noxide. Biochem Pharmacol 31:2823–2827, 1982

    PubMed  Google Scholar 

  67. Daniel P, Gaskell SJ, Bishop H, Campbell C, Nicholson RI: Determination of tamoxifen and biologically active metabolites in human breast tumors and plasma. Eur J Cancer Clin Oncol 17:1183–1189, 1981

    PubMed  Google Scholar 

  68. Coezy E, Borgna JL, Rochefort H: Tamoxifen and metabolites in MCF-7 cells: correlation between binding to estrogen receptor and inhibition of cell growth. Cancer Res 42:317–323, 1982

    PubMed  Google Scholar 

  69. Ruenitz PC, Toledo MM: Inhibition of rabbit liver microsomal oxidative metabolism and substate binding by tamoxifen and the geometric isomers of clomiphene. Biochem Pharmacol 29:1583–1587, 1980

    PubMed  Google Scholar 

  70. Sluyser M, Evers SG, De Goeij CCJ: Effects of monohydroxytamoxifen on mouse mammary tumors. Eur J Cancer Clin Oncol 17:1063–1065, 1981

    PubMed  Google Scholar 

  71. Jordan VC, Gosden B: Importance of the alkylaminoethoxy side-chain for the estrogenic and antiestrogenic actions of tamoxifen and trioxifene in the immature rat uterus. Mol Cell Endocrinol 27:291–306, 1982

    PubMed  Google Scholar 

  72. Rose DP, Fischer AH, Jordan VC: Activity of the antioestrogen trioxifene against N-nitrosomethylurea-induced rat mammary carcinomas. Eur J Cancer 17:893–898, 1981

    Google Scholar 

  73. Black LJ, Good RL: Uterine bioassay of tamoxifen, trioxifene and a new estrogen antagonist (LY 117018) in rats and mice. Life Sci 26:1453–58, 1980

    PubMed  Google Scholar 

  74. Black LJ, Good RL: Evidence for biological action of the antiestrogens LY117018 and tamoxifen by difference mechanisms. Endocrinology 109:987–989, 1981

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Departments of Human Oncology and Pharmacology, Wisconsin Clinical Cancer Center, University of Wisconsin, 600 Highland Avenue, 53792, Madison, Wisconsin, USA

    V. Craig Jordan Ph.D., FAIC & C. Chem MRSC

Authors
  1. V. Craig Jordan Ph.D., FAIC
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. C. Chem MRSC
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Jordan, V.C., Chem, C. Laboratory studies to develop general principles for the adjuvant treatment of breast cancer with antiestrogens: Problems and potential for future clinical applications. Breast Cancer Res Tr 3 (Suppl 1), S73–S86 (1983). https://doi.org/10.1007/BF01855131

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF01855131

Keywords

Search

Navigation